Skip to main content
SpringerLink
Log in

Expression pattern of hTERT telomerase subunit gene in different stages of chronic myeloid leukemia

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

An Erratum to this article was published on 29 February 2016

Abstract

Telomerase is activated in chronic myeloid leukemia (CML); however, it is not known whether the catalytic telomerase reverse transcriptase subunit (hTERT) is vital in the progression of this disease. This study involved patients with CML in the chronic phase (pretreatment and after treatment), accelerated and blastic phase. Expression of the hTERT gene differed significantly among the four major groups (p < 0.05). We also compared hTERT expression according to demographic parameter such as age and sex, and found no significant differences (p > 0.05). Taken together, our findings suggest the importance of hTERT as a valuable molecular marker in the follow-up of patients with CML, which may have clinical implications for the prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds) (2006) Williams hematology, 7th edn. McGraw-Hill, New York

    Google Scholar 

  2. Loffler H, Bergman J, Hochhaus A, Hehlmann R, Krämer A (2001) The German CML Study Group. Reduced risk for chronic myelogenous leukemia in individuals with cytochrome P-450 gene polymorphism CYPIAI *2A. Blood 98(13):3874–3881

    Article  CAS  Google Scholar 

  3. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al (2006) Gene expression change associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103(8):2794–2799

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Savona M, Talpaz M (2008) Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8(5):341–350

    Article  CAS  PubMed  Google Scholar 

  5. Cheung AL, Deng W (2008) Telomere dysfunction, genome instability and cancer. Front Biosci 1(13):2075–2090

    Article  Google Scholar 

  6. Ram R, Uziel O, Lahav M (2005) The importance of the telomere and telomerase system in hematological malignancies. Leuk Lymphoma 46(8):1121–1135

    Article  CAS  PubMed  Google Scholar 

  7. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K (2002) Telomeres and telomerase in hematologic neoplasia. Oncogene 21(4):680–687

    Article  CAS  PubMed  Google Scholar 

  8. Bock O, Serinsöz E, Schlué J, Kreipe H (2004) Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res 28(5):457–460

    Article  CAS  PubMed  Google Scholar 

  9. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MAS (2000) Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 60(3):610–617

    CAS  PubMed  Google Scholar 

  10. Deng Y, Chang S (2007) Role of telomeres and telomerase in genomic instability, senescence and cancer. Lab Invest 87(11):1071–1076

    Article  CAS  PubMed  Google Scholar 

  11. Padmanabhan P, Otero J, Ray P, Paulmurugan R, Hoffman AR, Gambhir SS et al (2006) Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct. J Nucl Med 47(2):270–277

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K (1997) Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 11(2):190–194

    Article  CAS  PubMed  Google Scholar 

  13. Xu D, Gruber A, Peterson C, Pisa P (1998) Telomerase activity and the expression of telomerase components in acute myelogenous leukemia. Br J Haematol 102(5):1367–1375

    Article  CAS  PubMed  Google Scholar 

  14. Bièche I, Noguès C, Paradis V, Olivi M, Bedossa P, Lidereau R et al (2000) Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6(2):452–459

    PubMed  Google Scholar 

  15. Kirkpatrick KL, Clark G, Ghilchick M, Newbold RF, Mokbel K (2003) hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 29(4):321–326

    Article  CAS  PubMed  Google Scholar 

  16. Ghaffari SH, Shayan-Asl N, Jamialahmadi AH et al (2008) Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol 19:1927–1934

    Article  CAS  PubMed  Google Scholar 

  17. Yoo J, Park SY, Kang SJ, Kim BK, Shim SI, Kang CS (2003) Expression of telomerase activity, human telomerase RNA and telomerase reverse transcriptase in gastric adenocarcinomas. Mod Pathol 16(7):700–707

    Article  PubMed  Google Scholar 

  18. Hu LH, Chen FH, Li YR, Wang L (2004) Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer. World J Gastroenterol 10(23):3514–3517

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS et al (2005) hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 79(4):267–273

    Article  CAS  PubMed  Google Scholar 

  20. Zhu K, Qu D, Sakamoto T, Fukasawa I, Hayashi M, Inaba N (2008) Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors. Arch Gynecol Obstet 277(1):15–19

    Article  CAS  PubMed  Google Scholar 

  21. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ et al (2003) Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 97(5):1248–1252

    Article  CAS  PubMed  Google Scholar 

  22. Yamada O, Kawauchi K, Akiyama M, Ozaki K, Motoji T, Adachi T et al (2008) Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk Lymphoma 49(6):1168–1177

    Article  CAS  PubMed  Google Scholar 

  23. Bagheri N, Mortazavi Y, Ghafari SH, Alimoghadam K, Pourfatoullah AA, Shayan N et al (2008) Analysis of telomere length change in chronic and blastic phases of chronic myelogenous leukemia. SJIBTO 5(1):9–15

    Google Scholar 

  24. Ohyashiki K, Iwama H, Tauchi T, Shimamoto T, Hayashi S, Ando K et al (2000) Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia. Leuk Lymphoma 40(1–2):49–56

    Article  CAS  PubMed  Google Scholar 

  25. Brümmendorf TH, Holyoake TL, Rufer N et al (2009) Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 95(6):1883–1890

    Google Scholar 

  26. Kimura A, Ohmichi M, Kawagoe J et al (2004) Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 23:4505–4515

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a research grant from Tehran University of Medical Sciences. We thank all the participants in this study for their help. We also thank all the doctors, nurses and other clinical staff of the Hematology/Oncology and BMT Research Center at Shariati Hospital in Tehran for their generous assistance, and K. Shashok (AuthorAID in the Eastern Mediterranean) for improving the use of English in the manuscript. We also thanks Mr. A. R. Taranejoo for his graphic works.

Author information

Authors and Affiliations

  1. Department of Biomedicine Allied Medical School, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

    Ali Amini

  2. Hematology-Oncology and BMT Research Center, Shariaty Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Seyed Hamidollah Ghaffari, Kamran Alimoghadam & Ardeshir Ghavamzadeh

  3. Department of Pathology and Molecular Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    Yousef Mortazai

  4. Department of Medical Genetics, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

    Karim Daliri

  5. Department of Chemical Engineering, Monash University, Melbourne, Australia

    Shahrouz Taranejoo

Authors
  1. Ali Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seyed Hamidollah Ghaffari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yousef Mortazai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karim Daliri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shahrouz Taranejoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kamran Alimoghadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ardeshir Ghavamzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yousef Mortazai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amini, A., Ghaffari, S.H., Mortazai, Y. et al. Expression pattern of hTERT telomerase subunit gene in different stages of chronic myeloid leukemia. Mol Biol Rep 41, 5557–5561 (2014). https://doi.org/10.1007/s11033-014-3472-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3472-3

Keywords

Search

Navigation